Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

OBJECTIVES Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). The pathological pathways involved in fibrogenesis in IPF and interstitial lung disease associated with systemic sclerosis (SSc-ILD) show commonalities; both involve fibroblast activation, myofibroblast accumulation and deposition of extracellular matrix. The SENSCIS™ trial is a randomised, placebo-controlled Phase III trial that will evaluate the efficacy and safety of nintedanib in patients with SSc-ILD (NCT02597933). METHODS Approximately 520 patients with SSc (based on 2013 American College of Rheumatology/European League Against Rheumatism criteria) and ILD (≥10% fibrosis of the lungs, confirmed by central assessment of chest high resolution computed tomography), forced vital capacity (FVC) ≥40% predicted and diffusing capacity for carbon monoxide of 30-89% predicted will be enrolled. Patients will be randomised (1:1) to nintedanib 150 mg twice daily or placebo, stratified by the presence of anti-topoisomerase I antibody. To reflect real-world management, patients receiving prednisone (≤10 mg/day) and/or a stable dose of mycophenolate or methotrexate, will be eligible. The primary endpoint is the annual rate of decline in FVC (mL/ year) assessed over 52 weeks. Patients will remain on blinded study treatment until the last patient completes 52 weeks of treatment or for a maximum of 100 weeks of treatment. Key secondary endpoints are absolute changes from baseline in modified Rodnan skin score and St George's Respiratory Questionnaire at week 52. RESULTS Recruitment for the trial began in November 2015. CONCLUSIONS This trial will assess the efficacy and safety of nintedanib in patients with SSc-ILD.

[1]  N. Leidy,et al.  Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.

[2]  R. Elashoff,et al.  Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.

[3]  V. Strand,et al.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group , 2015, The Journal of Rheumatology.

[4]  L. Richeldi,et al.  Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis , 2015, Respiratory Research.

[5]  O. Distler,et al.  Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[6]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[7]  G. Schett,et al.  Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[8]  S. Harari,et al.  Cellular interactions in the pathogenesis of interstitial lung diseases , 2015, European Respiratory Review.

[9]  K. Brown,et al.  The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review , 2014, Health and Quality of Life Outcomes.

[10]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[11]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[12]  Ami A. Shah,et al.  Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials , 2013, Thorax.

[13]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[14]  M. Schmidinger Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[15]  R. Gay,et al.  Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis , 2013, Annals of the rheumatic diseases.

[16]  S. Douma,et al.  Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naïve scleroderma patients , 2012, Modern rheumatology.

[17]  R. Elashoff,et al.  Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. , 2012, Chest.

[18]  R. Steele,et al.  Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.

[19]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[20]  R. Giacomelli,et al.  Angiogenic cytokines and growth factors in systemic sclerosis. , 2011, Autoimmunity reviews.

[21]  J. Pablos,et al.  Fibroblast abnormalities in the pathogenesis of systemic sclerosis , 2011, Expert review of clinical immunology.

[22]  Rosa M. Estrada-Y.-Martin,et al.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort , 2010, Arthritis research & therapy.

[23]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[24]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[25]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[26]  J. Zwerina,et al.  Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. , 2008, Arthritis and rheumatism.

[27]  B. Thombs,et al.  The relationship of dyspnoea to function and quality of life in systemic sclerosis , 2007, Annals of the rheumatic diseases.

[28]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[29]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[30]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[31]  R. Scorza,et al.  Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. , 2006, Rheumatology.

[32]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[33]  M. Suarez‐Almazor,et al.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.

[34]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[35]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[36]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[37]  Shaf Keshavjee,et al.  A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[38]  M. Marco,et al.  Cyclophosphamide versus placebo: effect on FVC , 2011 .

[39]  P. Lachenbruch,et al.  The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. , 1998, The Journal of rheumatology.